CoChat

T Cell Responses to Human Endogenous Retroviruses in HIV-1 Infection

Open access

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

Abstract

Human endogenous retroviruses (HERVs) are remnants of ancient infectious agents that have integrated into the human genome. Under normal circumstances, HERVs are functionally defective or controlled by host factors. In HIV-1-infected individuals, intracellular defense mechanisms are compromised. We hypothesized that HIV-1 infection would remove or alter controls on HERV activity. Expression of HERV could potentially stimulate a T cell response to HERV antigens, and in regions of HIV-1/HERV similarity, these T cells could be cross-reactive. We determined that the levels of HERV production in HIV-1-positive individuals exceed those of HIV-1-negative controls. To investigate the impact of HERV activity on specific immunity, we examined T cell responses to HERV peptides in 29 HIV-1-positive and 13 HIV-1-negative study participants. We report T cell responses to peptides derived from regions of HERV detected by ELISPOT analysis in the HIV-1-positive study participants. We show an inverse correlation between anti-HERV T cell responses and HIV-1 plasma viral load. In HIV-1-positive individuals, we demonstrate that HERV-specific T cells are capable of killing cells presenting their cognate peptide. These data indicate that HIV-1 infection leads to HERV expression and stimulation of a HERV-specific CD8+ T cell response. HERV-specific CD8+ T cells have characteristics consistent with an important role in the response to HIV-1 infection: a phenotype similar to that of T cells responding to an effectively controlled virus (cytomegalovirus), an inverse correlation with HIV-1 plasma viral load, and the ability to lyse cells presenting their target peptide. These characteristics suggest that elicitation of anti-HERV-specific immune responses is a novel approach to immunotherapeutic vaccination. As endogenous retroviral sequences are fixed in the human genome, they provide a stable target, and HERV-specific T cells could recognize a cell infected by any HIV-1 viral variant. HERV-specific immunity is an important new avenue for investigation in HIV-1 pathogenesis and vaccine design.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.ppat.0030165

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Plasma RNA Levels of HERV-K in HIV-1-Positive and -Negative Individuals' Plasma Levels of a HERV-K transcript derived from the envelope region were measured as a percentage relative to a standard derived from peripheral blood cells. The p-value was determined with the Mann-Whitney test.
Figure 1 Plasma RNA Levels of HERV-K in HIV-1-Positive and -Negative Individuals' Plasma Levels of a HERV-K transcript derived from the envelope region were measured as a percentage relative to a standard derived from peripheral blood cells. The p-value was determined with the Mann-Whitney test.CC BY · PubMed Central
Figure 2 HERV/HIV-1 Amino Acid Alignments Alignments were anchored based on short regions of similarity identified with BLAST [38] short nearly exact match search settings, which included both amino acid similarity estimated with evolutionary matrices (not shown in this figure) and identity. (A) HIV-1 HXB-2 and HERV-K (gi|5802821) showing a segment of the RT protein. Sequence numbering shown is based on position within individual accessions. Identical amino acids are shown in bold. (B) Short regions of similarity between reading frames within different HERV insertions [17,18] in the human genome and HIV-1 HXB-2 and their correspondence to regions of HIV-1. NT is shown when the region in HIV-1 was not a known CD8+ T cell epitope and the HIV-1 peptide was not included in the study.
Figure 2 HERV/HIV-1 Amino Acid Alignments Alignments were anchored based on short regions of similarity identified with BLAST [38] short nearly exact match search settings, which included both amino acid similarity estimated with evolutionary matrices (not shown in this figure) and identity. (A) HIV-1 HXB-2 and HERV-K (gi|5802821) showing a segment of the RT protein. Sequence numbering shown is based on position within individual accessions. Identical amino acids are shown in bold. (B) Short regions of similarity between reading frames within different HERV insertions [17,18] in the human genome and HIV-1 HXB-2 and their correspondence to regions of HIV-1. NT is shown when the region in HIV-1 was not a known CD8+ T cell epitope and the HIV-1 peptide was not included in the study.CC BY · PubMed Central
Figure 3 T Cell Responses to HERV and HIV-1 Antigens in HIV-1-Positive and -Negative Individuals Measured by Interferon-γ ELISPOT HERV peptides were grouped according to their similarity to HIV-1 peptide sequence, with “Unique HERV Peptides” having three or fewer amino acids in common with an HIV-1 peptide, and “HERV Peptides Similar to HIV-1” having four or more peptides in common with HIV-1. Subsets of peptides were tested in each patient, with the number tested (n = 6–23) varying depending on HLA type. Values shown for responses are normalized per peptide within each grouping (i.e., the sum of the response values to all peptides tested divided by the number of peptides tested for each patient). The individual peptide responses that are summarized in this figure are detailed in Figure S3. Responses in HIV-1-positive individuals are shown as closed circles and in HIV-1-negative individuals as open circles. Responses to all HERV peptides were measured for HCV+ individuals and are shown as filled triangles. p-Values are derived from the Mann-Whitney test.
Figure 3 T Cell Responses to HERV and HIV-1 Antigens in HIV-1-Positive and -Negative Individuals Measured by Interferon-γ ELISPOT HERV peptides were grouped according to their similarity to HIV-1 peptide sequence, with “Unique HERV Peptides” having three or fewer amino acids in common with an HIV-1 peptide, and “HERV Peptides Similar to HIV-1” having four or more peptides in common with HIV-1. Subsets of peptides were tested in each patient, with the number tested (n = 6–23) varying depending on HLA type. Values shown for responses are normalized per peptide within each grouping (i.e., the sum of the response values to all peptides tested divided by the number of peptides tested for each patient). The individual peptide responses that are summarized in this figure are detailed in Figure S3. Responses in HIV-1-positive individuals are shown as closed circles and in HIV-1-negative individuals as open circles. Responses to all HERV peptides were measured for HCV+ individuals and are shown as filled triangles. p-Values are derived from the Mann-Whitney test.CC BY · PubMed Central
Figure 4 Cross-Sectional and Longitudinal ELISPOT Responses to HIV-1- and HERV-Derived Peptides and Sequence Variants in HIV-1-Positive Study Participants (A) Responses in five HIV-1 positive study participants to the unique HERV peptide HERV-L IQ10. (B) A titration of peptide concentrations for HERV-L IQ10 (open green triangles) peptides for an HIV-1-positive study participant. (C) Responses in three individuals to a unique HERV peptide are shown as inverted green triangles. HIV-1 plasma viral loads are represented as filled red diamonds and are determined with clinical assays for viral load (bDNA and PCR assays). (D) Responses in two representative HIV+ study participants to an HIV-1 and HERV peptide pair with a high level of amino acid identity are shown in blue as open and filled circles, respectively. (E) Responses in three study participants to an HLA-A2-restricted HIV-1 epitope peptide (HIV RT VL9) and a HERV-L peptide (HERV-L II9) are shown, along with responses to three intermediate sequence variant peptides in which selected amino acids in the HIV-1 epitope were replaced with the equivalent amino acid found in the HERV peptide.
Figure 4 Cross-Sectional and Longitudinal ELISPOT Responses to HIV-1- and HERV-Derived Peptides and Sequence Variants in HIV-1-Positive Study Participants (A) Responses in five HIV-1 positive study participants to the unique HERV peptide HERV-L IQ10. (B) A titration of peptide concentrations for HERV-L IQ10 (open green triangles) peptides for an HIV-1-positive study participant. (C) Responses in three individuals to a unique HERV peptide are shown as inverted green triangles. HIV-1 plasma viral loads are represented as filled red diamonds and are determined with clinical assays for viral load (bDNA and PCR assays). (D) Responses in two representative HIV+ study participants to an HIV-1 and HERV peptide pair with a high level of amino acid identity are shown in blue as open and filled circles, respectively. (E) Responses in three study participants to an HLA-A2-restricted HIV-1 epitope peptide (HIV RT VL9) and a HERV-L peptide (HERV-L II9) are shown, along with responses to three intermediate sequence variant peptides in which selected amino acids in the HIV-1 epitope were replaced with the equivalent amino acid found in the HERV peptide.CC BY · PubMed Central
Figure 5 Phenotypic Profile Comparison of HIV-1-, HERV-, and CMV-Specific T Cells Measured by Multicolor Cytokine Flow Cytometry (A) Phenotypic characterization of cytokine producing cells (see Text S1) from two HIV-1-positive study participants for the markers CCR7, CD27, CD28, and CD45RA are shown as pie charts. The colors in the pie charts correspond to the phenotypic categories delineated in the table below them. (B) A subset of the data from (A) is shown, highlighting comparisons of specific phenotypes. The percentages of CD45RA+ (unfilled bars) and CD45RA− (filled bars) T cells are shown in the panels in the left column. The panels in the right column detail the percentages of CD28− T cells from the two study participants.
Figure 5 Phenotypic Profile Comparison of HIV-1-, HERV-, and CMV-Specific T Cells Measured by Multicolor Cytokine Flow Cytometry (A) Phenotypic characterization of cytokine producing cells (see Text S1) from two HIV-1-positive study participants for the markers CCR7, CD27, CD28, and CD45RA are shown as pie charts. The colors in the pie charts correspond to the phenotypic categories delineated in the table below them. (B) A subset of the data from (A) is shown, highlighting comparisons of specific phenotypes. The percentages of CD45RA+ (unfilled bars) and CD45RA− (filled bars) T cells are shown in the panels in the left column. The panels in the right column detail the percentages of CD28− T cells from the two study participants.CC BY · PubMed Central
Figure 6 Inverse Correlation between Anti-HERV T Cell Responses and HIV-1 Plasma Viral Load PBMCs from 20 HIV-1-positive individuals not on treatment were analyzed by ELISPOT for HERV responses. The mean response (>50 SFU/million PBMCs) values for all HERV peptides tested had a significant inverse correlation to HIV-1 plasma viral load (Spearman, two-tailed, r = −0.49, p = 0.03) and by linear regression (r 2 = 0.39, p = 0.003) as shown in the figure.
Figure 6 Inverse Correlation between Anti-HERV T Cell Responses and HIV-1 Plasma Viral Load PBMCs from 20 HIV-1-positive individuals not on treatment were analyzed by ELISPOT for HERV responses. The mean response (>50 SFU/million PBMCs) values for all HERV peptides tested had a significant inverse correlation to HIV-1 plasma viral load (Spearman, two-tailed, r = −0.49, p = 0.03) and by linear regression (r 2 = 0.39, p = 0.003) as shown in the figure.CC BY · PubMed Central
Figure 7 HERV-Specific T Cells Lyse HERV Peptide-Pulsed Targets HERV-L IQ10-specific T cells were tested against autologous B cells pulsed with HERV-L IQ10 peptide (open inverted green triangles), control peptide (filled squares), or no peptide (open squares) in independent peptide-stimulated expansions from two HIV-positive study participants.
Figure 7 HERV-Specific T Cells Lyse HERV Peptide-Pulsed Targets HERV-L IQ10-specific T cells were tested against autologous B cells pulsed with HERV-L IQ10 peptide (open inverted green triangles), control peptide (filled squares), or no peptide (open squares) in independent peptide-stimulated expansions from two HIV-positive study participants.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 1

  1. CoffinJMHughesSHVarmusHE 1997 Retroviruses Cold Spring Harbor (New York) Cold Spring Harbor Laboratory Press

Cited by

Items 101–132 of 132

Metadata

Authors
Garrison, K. E., Jones, R. B., Meiklejohn, D. A., Anwar, N., Ndhlovu, L. C., Chapman, J. M., Erickson, A. L., Agrawal, A., Spotts, G., Hecht, F. M., Rakoff-Nahoum, S., Lenz, J., Ostrowski, M. A., & Nixon, D. F.
Affiliations
  • University of California, San Francisco (US)
  • University of Toronto (CA)
  • Gladstone Institutes (US)
  • San Francisco General Hospital (US)
  • Yale University (US)
  • Albert Einstein College of Medicine (US)
  • St. Michael's Hospital (CA)
Corresponding author
  • Garrison, Keith E
  • Jones, R. Brad
Venue
PLoS Pathogens
Published
2007-11-09
Volume
3
Issue
11
Pages
e165
ISSN
  • 1553-7366 (ISSN-L)
  • 1553-7374
OpenAlex
W2157279932
Cited by
131
References
38
Citations by year
2025: 8 · 2024: 6 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 7 · 2019: 6 · 2018: 6 · 2017: 6 · 2016: 11 · 2015: 6 · 2014: 12 · 2013: 13 · 2012: 10
FWCI
2.14
Type
journal article
Language
en
Open access
Locations
  • PLoS Pathogens (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Institutes of Health
  • Faculty of Medical and Health Sciences, University of Auckland
  • National Institute of Allergy and Infectious Diseases (R01AI076059)
Topics
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
human endogenous retroviruses, HIV-1 infection, T cell response, immunological cross-reactivity, viral load, HERV expression, cytomegalovirus, HIV vaccine design
MeSH terms
Antigens, Viral, Cross-Sectional Studies, Flow Cytometry, Humans, RNA, Viral, Cohort Studies, HIV-1, HIV Infections, CD8-Positive T-Lymphocytes, Viral Load, Endogenous Retroviruses, Reverse Transcriptase Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.